Product image of Nimotop (Nimodipine) supplied by GNH India

Nimotop

Active Ingredient:
Nimodipine
Origin:
EU

Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, improving cerebral blood flow in affected patients.

GNH India supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with full regulatory compliance and quality assurance. Our distribution network ensures timely delivery across multiple regions.

Manufacturer / TM Owner

Laboratoire Xo

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimodipine is a calcium channel blocker used in the management of cerebrovascular complications.

  • Subarachnoid hemorrhage: prevention of cerebral vasospasm to reduce delayed ischemic neurological deficits.
  • Aneurysmal rupture recovery: management of delayed cerebral ischemia by maintaining arterial patency.
  • Neurocritical care: support of cerebral perfusion in patients at risk of vasospasm.

How It Works

  • Nimodipine selectively antagonizes L‑type calcium channels on smooth‑muscle cells of cerebral arteries. By blocking calcium influx, it induces vasodilation of intracranial vessels, thereby increasing cerebral blood flow while having minimal impact on systemic blood pressure. This preferential cerebral vasodilation underlies its effectiveness in preventing vasospasm after subarachnoid hemorrhage.

Side Effects

Nimodipine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: warmth and redness of skin.
  • Dizziness: sensation of light‑headedness.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Severe hypotension: profound blood pressure reduction requiring intervention.
  • Myocardial infarction: rare cardiac ischemic events.
  • Bradycardia: markedly slow heart rate.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Seizures: infrequent neurologic events.

Precautions & Warnings

When using Nimotop, clinicians should observe several precautionary measures to ensure patient safety.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: use with caution; monitor liver enzymes.
  • Hypotension: observe blood pressure regularly during infusion.
  • Concomitant vasodilators: avoid additive hypotensive effects.
  • Pregnancy: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Nimodipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations.
  • Combined use with beta‑blockers: may exacerbate bradycardia.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
  • Diuretics: may enhance hypotensive response.
  • Anticoagulants: monitor for bleeding if hypotension occurs.

Frequently Asked Questions

Nimotop is indicated for the prevention of cerebral vasospasm following subarachnoid hemorrhage. By reducing the risk of delayed ischemic neurological deficits, it helps maintain adequate cerebral blood flow in patients who have experienced a ruptured aneurysm.

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium‑mediated contraction, causing vasodilation of intracranial vessels and increasing cerebral perfusion without markedly lowering systemic blood pressure.

The dosage and infusion rate of Nimotop are determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety of Nimotop in pregnancy or lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimotop (nimodipine) is a dihydropyridine calcium‑channel blocker with high affinity for cerebral vessels, offering targeted vasodilation. Alternatives such as nicardipine or verapamil also provide vasodilatory effects but may have broader systemic actions. Nimodipine’s cerebral selectivity makes it a preferred option for subarachnoid hemorrhage‑related vasospasm.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from light and moisture, and keep it out of reach of children. Do not freeze or expose it to extreme temperatures.

Nimotop is supplied as an injectable solution for intravenous infusion. It is typically administered by a healthcare professional using a controlled infusion pump, with infusion rates and duration set according to the prescriber’s orders and patient monitoring.

Serious adverse events include severe hypotension, myocardial infarction, bradycardia, hepatic dysfunction, allergic reactions such as anaphylaxis, and, rarely, seizures. Patients should be monitored closely for signs of cardiovascular instability and liver enzyme changes during therapy.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any excipients, and in those with severe hypotension or uncontrolled cardiac arrhythmias. Caution is also advised for individuals with significant hepatic or renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT